Ryan Fukushima Sells 13,550 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 13,550 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the transaction, the chief executive officer owned 603,558 shares in the company, valued at approximately $26,598,801.06. The trade was a 2.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $46.18 on Friday. The company’s 50 day moving average price is $48.89 and its two-hundred day moving average price is $59.29. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The firm has a market cap of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the prior year, the business posted ($0.24) EPS. The business’s revenue was up 36.1% compared to the same quarter last year. Equities research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Wednesday, March 11th. Morgan Stanley cut their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. BTIG Research cut their price target on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a report on Friday, May 8th. Robert W. Baird initiated coverage on shares of Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target for the company. Finally, Guggenheim cut their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $68.64.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the last quarter. ARK Investment Management LLC lifted its stake in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after purchasing an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC bought a new position in Tempus AI in the 4th quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. lifted its stake in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.